JP2017075173A5 - - Google Patents

Download PDF

Info

Publication number
JP2017075173A5
JP2017075173A5 JP2016249232A JP2016249232A JP2017075173A5 JP 2017075173 A5 JP2017075173 A5 JP 2017075173A5 JP 2016249232 A JP2016249232 A JP 2016249232A JP 2016249232 A JP2016249232 A JP 2016249232A JP 2017075173 A5 JP2017075173 A5 JP 2017075173A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
amyloidosis
condition associated
pathological condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016249232A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017075173A (ja
JP6370361B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017075173A publication Critical patent/JP2017075173A/ja
Publication of JP2017075173A5 publication Critical patent/JP2017075173A5/ja
Application granted granted Critical
Publication of JP6370361B2 publication Critical patent/JP6370361B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016249232A 2008-03-21 2016-12-22 アルツハイマー病及び関連疾患の検出及び治療のための化合物及び組成物 Expired - Fee Related JP6370361B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3857108P 2008-03-21 2008-03-21
US61/038,571 2008-03-21

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014046341A Division JP6140090B2 (ja) 2008-03-21 2014-03-10 アルツハイマー病及び関連疾患の検出及び治療のための化合物及び組成物

Publications (3)

Publication Number Publication Date
JP2017075173A JP2017075173A (ja) 2017-04-20
JP2017075173A5 true JP2017075173A5 (enExample) 2017-11-24
JP6370361B2 JP6370361B2 (ja) 2018-08-08

Family

ID=41091569

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011501009A Expired - Fee Related JP5501339B2 (ja) 2008-03-21 2009-03-23 アルツハイマー病及び関連疾患の検出及び治療のための化合物及び組成物
JP2014046341A Expired - Fee Related JP6140090B2 (ja) 2008-03-21 2014-03-10 アルツハイマー病及び関連疾患の検出及び治療のための化合物及び組成物
JP2016249232A Expired - Fee Related JP6370361B2 (ja) 2008-03-21 2016-12-22 アルツハイマー病及び関連疾患の検出及び治療のための化合物及び組成物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2011501009A Expired - Fee Related JP5501339B2 (ja) 2008-03-21 2009-03-23 アルツハイマー病及び関連疾患の検出及び治療のための化合物及び組成物
JP2014046341A Expired - Fee Related JP6140090B2 (ja) 2008-03-21 2014-03-10 アルツハイマー病及び関連疾患の検出及び治療のための化合物及び組成物

Country Status (8)

Country Link
US (5) US8450466B2 (enExample)
EP (2) EP2268647B1 (enExample)
JP (3) JP5501339B2 (enExample)
CN (2) CN102046638B (enExample)
AU (1) AU2009225407B2 (enExample)
CA (2) CA2718035C (enExample)
MX (2) MX2010010314A (enExample)
WO (1) WO2009117728A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8257680B1 (en) 2004-02-24 2012-09-04 The General Hospital Corporation Catalytic radiofluorination
US9017724B2 (en) 2004-02-24 2015-04-28 The General Hospital Corporation Catalytic radiofluorination
US8450466B2 (en) 2008-03-21 2013-05-28 The General Hosptial Corporation Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
RU2577810C2 (ru) * 2010-08-16 2016-03-20 Когноптикс, Инк. Система и способ для обнаружения амилоидных белков
CA2824858A1 (en) 2011-01-18 2012-07-26 General Atomics Hydrolase enzyme substrates and uses thereof
US9855276B2 (en) 2012-10-25 2018-01-02 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
AU2014340182B2 (en) 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CN106573880B (zh) * 2014-03-19 2019-07-30 阿米达斯公司 淀粉样蛋白靶向剂及其使用方法
EP3506894B1 (en) 2016-08-31 2023-08-23 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
US10675365B2 (en) 2016-09-29 2020-06-09 Korea Atomic Energy Research Institute Curcumin derivative, method for producing same, and photo-acoustic imaging agent comprising same for detecting beta-amyloid plaque
WO2019017995A1 (en) 2017-07-20 2019-01-24 Aztherapies, Inc. FORMULATIONS OF CROMOLYNE SODIUM POWDER AND IBUPROFEN
WO2019232422A1 (en) 2018-05-31 2019-12-05 Amydis, Inc. Compositions and methods for detection of traumatic brain injury
JP2021529771A (ja) 2018-07-02 2021-11-04 ザ ジェネラル ホスピタル コーポレイション クロモリンナトリウムおよびα−ラクトースの粉末製剤
BR112021003156A2 (pt) 2018-08-23 2021-05-11 Seagen, Inc. composição, anticorpo que se liga ao tigit humano, formulação farmacêutica, polinucleotídeo isolado, vetor, célula hospedeira, métodos para a produção de um anticorpo que se liga ao tigit humano e de anticorpos afucosilados que se ligam a tigit e para o tratamento de um câncer, e, kit.
US12383528B2 (en) 2018-12-10 2025-08-12 The General Hospital Corporation Cromolyn esters and uses thereof
JP2023520580A (ja) 2020-04-06 2023-05-17 ザ ジェネラル ホスピタル コーポレイション コロナウイルス誘発炎症状態の処置方法
JPWO2022059776A1 (enExample) * 2020-09-17 2022-03-24
WO2022146914A1 (en) 2020-12-28 2022-07-07 The General Hospital Corporation Cromolyn derivatives and uses thereof
KR20240148356A (ko) 2022-02-07 2024-10-11 마틴 제이. 모스코비츠 극저온 수술 장치와 재료 및 그 사용 방법

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1009897A (en) 1911-03-27 1911-11-28 Us Electrographic Company Projection apparatus.
CH375356A (de) 1959-03-25 1964-02-29 Sandoz Ag Verfahren zur Herstellung von neuen substituierten Succinimiden
CH449628A (de) * 1962-04-16 1968-01-15 Sandoz Ag Verfahren zur Herstellung substituierter Succinimide
US3207780A (en) * 1962-11-15 1965-09-21 Upjohn Co 1-deoxy-1-guanidino-3-o-carbamoyl-scyllo-inositol and acylates thereof
US4069262A (en) 1977-03-07 1978-01-17 E. I. Du Pont De Nemours And Company Preparation of 2-fluoronitrobenzene
FR2498594A1 (fr) 1981-01-23 1982-07-30 Rhone Poulenc Ind Procede de preparation de monoesters d'acides carboxyliques b,g-insatures
US4446123A (en) 1982-10-13 1984-05-01 Hahnemann University Process of radioimaging the myocardium of mammals utilizing radiolabeled lipophilic cations
HUT36793A (en) 1983-06-27 1985-10-28 Sandoz Ag Process for producing new spirosuccunimide derivatives and pharmaceutical composition containing them
BE900003A (fr) * 1983-06-27 1984-12-27 Sandoz Sa Derives du spirosuccinimide utilisables comme medicaments.
US4606908A (en) 1983-10-04 1986-08-19 Washington Research Foundation Methods and compositions for plasma and organ imaging
EP0273659A1 (en) * 1986-12-27 1988-07-06 Takeda Chemical Industries, Ltd. Azaspiro compounds, their production and use
US4847082A (en) * 1987-01-21 1989-07-11 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
US5852029A (en) * 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
SE465348B (sv) 1990-06-14 1991-08-26 Nils Elander Mikrovaagsanordning foer behandling av precessvaetskor
US5139034A (en) * 1990-11-15 1992-08-18 Philip Morris Incorporated Smoking compositions containing a menthol-release additive
IT1244546B (it) * 1991-02-01 1994-07-15 Mediolanum Farmaceutici Spa Analoghi del fosfatidilinositolo inibitori della fosfolipasi c fosfatidilinositolo-specifica
US5315043A (en) 1992-02-05 1994-05-24 E. I. Du Pont De Nemours And Company Aromatic nucleophilic fluorination
US5264570A (en) * 1992-08-05 1993-11-23 General Electric Company Method for making 2-[18 F]fluoro-2-deoxy-D-glucose
US5493026A (en) 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
US6168776B1 (en) 1994-07-19 2001-01-02 University Of Pittsburgh Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
WO1997026919A2 (en) 1996-01-24 1997-07-31 Warner-Lambert Company Method of imaging amyloid deposits
JP3816570B2 (ja) * 1996-02-16 2006-08-30 塩水港精糖株式会社 アシル化剤
TW593290B (en) 1996-05-10 2004-06-21 Janssen Pharmaceutica Nv Alkylaminobenzothiazole and -benzoxazole derivatives
DE19624705A1 (de) * 1996-06-20 1998-01-08 Deutsches Krebsforsch Dendrimere auf Saccharid-Basis
US5817877A (en) 1996-09-23 1998-10-06 Yale University Metal-catalyzed amination of organic sulfonates to organic amines
US6187286B1 (en) 1996-12-27 2001-02-13 The General Hospital Corporation Tumor imaging agents, methods and kits
US6019957A (en) 1997-06-04 2000-02-01 The University Of Tennessee Research Corporation Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
WO1999012579A1 (en) 1997-09-08 1999-03-18 The General Hospital Corporation Imaging agents for early detection and monitoring of cardiovascular plaque
JP4177472B2 (ja) * 1997-10-02 2008-11-05 株式会社横浜国際バイオ研究所 窒素官能基を含有するアシル化剤及びその製造法
US6660832B1 (en) 1999-08-20 2003-12-09 Isis Pharmaceuticals, Inc. Macrocyclic compounds and preparation methods thereof
JP4116793B2 (ja) 1999-09-13 2008-07-09 良尋 高井 新規ニトロイミダゾール誘導体及びこれを含む画像診断薬
DE60010528T2 (de) 2000-06-12 2005-05-12 The University Of Florida Research Foundation, Gainesville Verfahren zur herstellung von fluorierten benzolen
UY27003A1 (es) 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
ES2274973T3 (es) 2001-04-23 2007-06-01 The Trustees Of The University Of Pennsylvania Inhibidores de la agregacion de placas amiloides y agentes de obtencion de imagenes diagnosticas.
AU2003217349B2 (en) 2002-02-06 2008-05-22 The Johns Hopkins University Non-invasive diagnostic imaging technology for mitochondria using radiolabeled lipophilic salts
DE10210195B4 (de) * 2002-03-07 2005-12-15 Schwarz Pharma Ag Verwendung von 1,3-Diazaspiro-[4,5]decan-2,4-dithion zur Behandlung von Schmerz
US20080063599A1 (en) 2002-11-18 2008-03-13 Jorge Setoain Quinquer Compounds Which Can Be Used To Diagnose And Monitor Diseases Associated With The Formation Of Amyloid Protein Fibrils
CN100536837C (zh) * 2003-02-27 2009-09-09 乔安妮·麦克劳林 鲨肌醇在制备诊断试剂中的用途
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
GB0304640D0 (en) 2003-02-28 2003-04-02 Novartis Ag Organic compounds
US7295831B2 (en) 2003-08-12 2007-11-13 3E Technologies International, Inc. Method and system for wireless intrusion detection prevention and security management
WO2005016384A1 (ja) 2003-08-13 2005-02-24 Bf Research Institute, Inc. アミロイド蓄積性疾患のプローブ、アミロイド染色剤、アミロイド蓄積性疾患の治療および予防薬、ならびに神経原線維変化の診断プローブおよび染色剤
US8257680B1 (en) 2004-02-24 2012-09-04 The General Hospital Corporation Catalytic radiofluorination
EP2610234A1 (en) 2004-02-24 2013-07-03 The General Hospital Corporation Catalytic radiofluorination
US9017724B2 (en) 2004-02-24 2015-04-28 The General Hospital Corporation Catalytic radiofluorination
KR100578732B1 (ko) * 2004-03-05 2006-05-12 학교법인 포항공과대학교 분자 수송체로서의 이노시톨 유도체 및 이의 제조방법
BRPI0517672A (pt) * 2004-11-05 2008-10-14 Wyeth Corp modalidades de formação de imagens para seleção terapêutica de doença de alzheimer
US20060189582A1 (en) * 2004-11-17 2006-08-24 Mclaurin Joanne Compositions and methods for treatment of disorders of protein aggregation
US7138540B1 (en) 2005-09-06 2006-11-21 Institute Of Nuclear Energy Research Convenient method for the preparation of new precursor of no-carrier-added O-(2-[18F]fluoroethyl)-L-Tyrosine)
WO2007119108A2 (en) * 2005-10-13 2007-10-25 Waratah Pharmaceuticals Inc. Inositol derivatives and their uses in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence
JP2007194369A (ja) * 2006-01-18 2007-08-02 Toei Kogyo Kk 高出力Ｅｒ：ＹＡＧレーザ装置
NO325976B1 (no) * 2006-01-26 2008-08-25 Gba Marine As Anordning for absorpsjon av gass eller damp i vaeske og fremgangsmate ved reintrodusering av damp eller gass i vaeske som gassen eller dampen stammer fra
US20070197452A1 (en) * 2006-02-17 2007-08-23 Mclaurin Joanne Treatment of amyloid-related diseases
KR20090119966A (ko) 2007-03-01 2009-11-23 바이엘 쉐링 파마 악티엔게젤샤프트 진단 영상화제로서의 18ｆ 플루오로-벤조일 표지된 생물학적 활성 화합물, 벤조트리아졸-1-일옥시-벤조일, 2,5-디옥소-피롤리딘-1-일옥시)벤조일 및 트리메틸암모니오-벤조일 전구체
WO2009014203A1 (ja) * 2007-07-26 2009-01-29 Hokko Chemical Industry Co., Ltd. （１，３，５／２，４，６）－１－フルオロ－２，３，４，５，６－シクロヘキサンペントールの製造方法
US8450466B2 (en) 2008-03-21 2013-05-28 The General Hosptial Corporation Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders
CA2747575A1 (en) 2008-12-22 2010-07-01 Keith Graham A method for synthesis of a radionuclide-labeled compound using an exchange resin
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
US20150246142A1 (en) 2012-09-25 2015-09-03 The Regents Of The University Of Michigan Imaging agents
US20170334804A1 (en) 2014-10-31 2017-11-23 The General Hospital Corporation F-18 labeled tracer and methods of manufacture

Similar Documents

Publication Publication Date Title
RU2017112747A (ru) Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции
CL2019001978A1 (es) Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo.
JP2016518337A5 (enExample)
EP3563849A3 (en) Combination therapies for the treatment of alzheimer's disease and related disorders
JP2017509667A5 (enExample)
AR111693A1 (es) Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga
JP2014507446A5 (enExample)
JP2013525444A5 (enExample)
JP2016522254A5 (enExample)
JP2016034978A5 (enExample)
MX379043B (es) Uso de sobetirome en el tratamiento de enfermedades de mielinización.
JP2017506624A5 (enExample)
WO2016087944A3 (en) Method for treating alzheimer's disease
JP2019516739A5 (enExample)
JP2017511377A5 (enExample)
JP2019535760A5 (ja) ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法
JP2019529514A5 (enExample)
JP2016501219A5 (enExample)
RU2016102092A (ru) Тауроурсодезоксихолевая кислота (tudca) для применения в лечении нейродегенеративных нарушений
JP2009178162A5 (enExample)
JP2018505899A5 (enExample)
IL286818A (en) Mirikizumab for use in a method of treating crohns disease
JP2014518280A5 (enExample)
JP2017514829A5 (enExample)
JP2017511372A5 (enExample)